These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30804716)

  • 1. Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation.
    Latt NL
    Gastroenterol Hepatol (N Y); 2018 Dec; 14(12):687-705. PubMed ID: 30804716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.
    Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM
    Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
    Durand CM; Bowring MG; Brown DM; Chattergoon MA; Massaccesi G; Bair N; Wesson R; Reyad A; Naqvi FF; Ostrander D; Sugarman J; Segev DL; Sulkowski M; Desai NM
    Ann Intern Med; 2018 Apr; 168(8):533-540. PubMed ID: 29507971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
    Czarnecka P; Czarnecka K; Tronina O; Baczkowska T; Durlik M
    Ren Fail; 2022 Dec; 44(1):434-449. PubMed ID: 35260039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
    Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
    Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
    Chute DF; Chung RT; Sise ME
    Kidney Int; 2018 Mar; 93(3):560-567. PubMed ID: 29325996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective.
    Jadoul M; Martin P
    Blood Purif; 2017; 43(1-3):206-209. PubMed ID: 28114144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
    Liu CH; Kao JH
    Hepatol Int; 2022 Oct; 16(5):1001-1019. PubMed ID: 35876967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    Cacoub P; Desbois AC; Isnard-Bagnis C; Rocatello D; Ferri C
    J Hepatol; 2016 Oct; 65(1 Suppl):S82-S94. PubMed ID: 27641990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC
    Gastroenterol Hepatol (N Y); 2017 Dec; 13(12 Suppl 5):1-24. PubMed ID: 29950953
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Direct-acting antiviral agents, hepatitis C and dialysis: an update].
    Fabrizi F; Lampertico P; Messa P
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
    Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
    Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant.
    Fabrizi F; Alonso C; Palazzo A; Anders M; Reggiardo MV; Cheinquer H; Zuain MGV; Figueroa S; Mendizabal M; Silva M; Ridruejo E;
    Ann Hepatol; 2021; 25():100337. PubMed ID: 33684523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs.
    Fabrizi F; Cerutti R; Alfieri CM; Messa P
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories.
    Mendizabal M; Reddy KR
    J Viral Hepat; 2017 Jun; 24(6):442-453. PubMed ID: 28107583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.